Nonoperative approach feasible in advanced colon cancer

August 9, 2012
Nonoperative approach feasible in advanced colon cancer
Treating patients with surgically unresectable metastatic colon cancer and an asymptomatic intact primary tumor with bevacizumab and infusional fluorouracil, leucovorin, and oxaliplatin chemotherapy is a viable and safe option, according to research published online Aug. 6 in the Journal of Clinical Oncology.

(HealthDay) -- Treating patients with surgically unresectable metastatic colon cancer and an asymptomatic intact primary tumor with bevacizumab and infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy is a viable and safe option, according to research published online Aug. 6 in the Journal of Clinical Oncology.

Laurence E. McCahill, M.D., of the University of Pittsburg, and colleagues conducted a multicenter, prospective, phase II trial involving 90 patients with surgically unresectable metastatic colon cancer and an intact asymptomatic primary tumor. Participants were treated with mFOLFOX6 plus without resection of the primary tumor.

During a median follow-up of 20.7 months, the researchers found that 14 percent of patients experienced major morbidity related to their intact primary tumor, with two patients dying and 10 requiring surgery for obstruction, perforation, or abdominal pain. The cumulative incidence of major morbidity over 24 months was 16.3 percent. Eight tumors were resected without a morbidity event for attempted cure, and three others were resected for other reasons. Two patients only experienced minor morbidity events. The median overall survival was 19.9 months.

"Overall, this study identified that an initial nonoperative approach, using mFOLFOX6 combined with bevacizumab is a viable and safe option for patients faced with the dilemma of advanced, likely incurable ," the authors write. "The majority of patients (84 percent) were able to receive initial systemic therapy to better control distant disease and to avoid potential delays and complications or death related to initial surgical resection without compromising overall survival."

Two authors disclosed financial ties to the pharmaceutical industry.

Explore further: Adding drug to chemotherapy following colon cancer surgery does not improve disease-free survival

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

High survival with surgery in low-risk neuroblastoma

April 25, 2012

(HealthDay) -- Surgery alone results in high five-year event-free and overall survival (EFS and OS) rates for patients with low-risk stage 2a and 2b neuroblastoma (NBL), according to research published online April 23 in ...

ASCO: Continuing avastin with 2nd-line chemo ups survival

June 5, 2012

(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...

Chemo combo promising for pancreatic neuroendocrine tumors

July 13, 2012

(HealthDay) -- The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors (NETs), according to a study published online July 9 in the Journal of Clinical Oncology.

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.